For some men with advanced prostate cancer, radioligand therapy — an innovative, targeted approach — represents hope for longer survival and better disease control.
Prostate cancer that progresses despite hormone therapy can be challenging to treat, but a targeted radiation approach with a therapy called Pluvicto (lutetium-177 vipivotide tetraxetan) offers a promising new option.
Here, top doctors in the Philadelphia area explain how the treatment works and who is eligible.
Content independently created by SurvivorNet with support from Novartis Pharmaceuticals Corp.
Dr. William Kevin Kelly
Thomas Jefferson University
Even when prostate cancer continues to progress after hormone therapy, new and effective options are emerging to help patients live longer and maintain a good quality of life
Dr. Leonard Gomella
Thomas Jefferson University
By combining targeted radiation with precision delivery, Pluvicto (lutetium-177 vipivotide tetraxetan) can selectively destroy cancer cells while preserving surrounding healthy tissue.
Dr. Vivek Narayan
University of Pennsylvania
Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells, delivering systemic radiation that minimizes harm to healthy tissue.
Dr. William Kevin Kelly
Thomas Jefferson University
Radioligand therapy uses radio-labeled antibodies to deliver targeted radiation directly to prostate cancer cells, minimizing damage to healthy tissue, resulting in fewer and less grueling side effects.
Dr. William Tester
Thomas Jefferson University
Castration-resistant prostate cancer, or CRPC, happens when the patient stops responding to this androgen deprivation therapy (ADT). There are several treatment approaches available at this stage.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
